4
Changes in Ownership
Dianthus Therapeutics, Inc. /DE/ Filed Acc 0000899243-18-018341
Director bought 6,600 shares at $15.00 ($99,000)
- Director acquired 28,076 shares (conversion)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Scadden David Director | 2018-06-25 | Conversion | +28,076 | 221,575 | D | ||
| Scadden David Director | 2018-06-25 | Purchase | +6,600 | $15.00 | $99,000 | 228,175 | D |
| Derivatives | |||||||
| Scadden David Director | 2018-06-25 | Conversion · Series A Preferred Stock | −50,025 | 0 | D | ||
| Scadden David Director | 2018-06-25 | Conversion · Series B Preferred Stock | −6,429 | 0 | D | ||
| Scadden David Director | 2018-06-25 | Conversion · Series C Preferred Stock | −16,094 | 0 | D | ||
| Open-market purchases · 6,600 sh · avg $15.00 · $99,000 | |||||||
Loading xslF345X03/doc4.xml…